Tech Company Financing Transactions

Tessera Therapeutics Funding Round

Tessera Therapeutics closed a $230 million Series B funding round on 1/13/2021. Backers included Alaska Permanent Fund, Altitude Life Science Ventures and SoftBank Vision Fund.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

55 Cambridge Pkwy. 800E
Cambridge, MA 02142
USA

Phone

Undisclosed

Website

www.tesseratherapeutics.com

Email Address

[email protected]

Overview

Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Geoffrey von Maltzahn

        

Chief Scientific Officer

Jacob Rubens

        

Vice President

Stephen Cleaver

        

Vice President

Cecilia Cotta-Ramusino

        

VP - Bus. Development

Vikram Ranade

        

Browse more venture capital transactions:

Prev: 1/13/2021: Gro Intelligence venture capital transaction
Next: 1/13/2021: Cardea Bio venture capital transaction

Share this article

About Database of VC Transactions

We do our best to document every notable VC transaction. All VC database entries on this site come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary